We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

53 hedge funds and large institutions have $108M invested in Fennec Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

337% more call options, than puts

Call options by funds: $1.55M | Put options by funds: $355K

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

143% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 7

23% more funds holding

Funds holding: 43 → 53 (+10)

1.9% more ownership

Funds ownership: 47.42% → 49.31% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less capital invested

Capital invested by funds: $120M → $108M (-$11.1M)

Holders
53
Holders Change
+10
Holders Change %
+23.26%
% of All Funds
0.84%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
17
Increased
20
Reduced
7
Closed
7
Calls
$1.55M
Puts
$355K
Net Calls
+$1.2M
Net Calls Change
-$1.66M

Top Buyers

Rank Fund Capital Flow
1
DCM
DG Capital Management
New York
+$2.12M
2
ACM
AIGH Capital Management
Maryland
+$1.5M
3
HFA
Harbert Fund Advisors
Alabama
+$1.39M
4
GJL
Gendell Jeffrey L
+$920K
5
Millennium Management
Millennium Management
New York
+$582K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$2.61M
2
EI
EAM Investors
California
-$1.69M
3
TA
Tamarack Advisers
California
-$592K
4
TS
Tamar Securities
California
-$513K
5
Two Sigma Investments
Two Sigma Investments
New York
-$253K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$285K -$193K -20,800 -38%
BCM
27
Bridgeway Capital Management
Texas
$285K – – –
Toronto Dominion Bank
28
Toronto Dominion Bank
Ontario, Canada
$204K +$236K +25,400 New
Goldman Sachs
29
Goldman Sachs
New York
$173K -$2.17K -234 -1%
Squarepoint
30
Squarepoint
New York
$170K +$189K +20,393 New
Janney Montgomery Scott
31
Janney Montgomery Scott
Pennsylvania
$166K +$186K +20,000 New
Geode Capital Management
32
Geode Capital Management
Massachusetts
$162K – – –
Citigroup
33
Citigroup
New York
$151K +$16.2K +1,742 +10%
Man Group
34
Man Group
United Kingdom
$140K -$126K -13,630 Closed
Marshall Wace
35
Marshall Wace
United Kingdom
$125K +$140K +15,066 New
JF
36
Jump Financial
Illinois
$118K -$62.8K -6,771 -32%
TMC
37
Trellus Management Company
Florida
$98.7K +$110K +11,861 New
LP
38
LMR Partners
United Kingdom
$94.9K +$106K +11,402 New
CSS
39
Cubist Systematic Strategies
Connecticut
$94K +$105K +11,304 New
BFM
40
Boothbay Fund Management
New York
$90K +$100K +10,818 New
Barclays
41
Barclays
United Kingdom
$80.7K +$4.05K +437 +5%
Bank of America
42
Bank of America
North Carolina
$56K +$42.1K +4,535 +206%
TRCT
43
Tower Research Capital (TRC)
New York
$26K +$241 +26 +0.8%
Point72 Asset Management
44
Point72 Asset Management
Connecticut
$25.8K +$28.8K +3,100 New
PMEF
45
Point72 Middle East FZE
United Arab Emirates
$25.7K +$28.6K +3,087 New
Osaic Holdings
46
Osaic Holdings
Arizona
$25.5K -$7.72K -832 -21%
SOW
47
State of Wyoming
Wyoming
$6.69K +$7.46K +804 New
UBS Group
48
UBS Group
Switzerland
$5.87K +$5.95K +641 +1,002%
TAM
49
Tucker Asset Management
Colorado
$4.16K +$4.64K +500 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$4K +$1.23K +133 +46%
1
2
3

FENC Hedge Fund Activity: Q1 2023 in Review

53 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2023, worth a combined $108M — down 9.2% from $120M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new FENC positions and 7 closed out — a net gain of 10 holders — while 20 added to existing stakes and 7 trimmed.

The largest buyer was DG Capital Management, adding an estimated $2.12M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.61M sold.

  • 53 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2023, up from 43 in Q4 2022.
  • Funds reported $108M of Fennec Pharmaceuticals stock for Q1 2023, down 9.2% quarter-over-quarter.
  • 17 funds opened new Fennec Pharmaceuticals positions in Q1 2023 and 7 closed out, a net change of +10 holders.
  • The largest Fennec Pharmaceuticals buyer in Q1 2023 was DG Capital Management, an estimated $2.12M added.
  • The largest Fennec Pharmaceuticals seller in Q1 2023 was Opaleye Management, an estimated $2.61M sold.

Based on aggregated 13F filings for Q1 2023.